Multiple Sclerosis Clinical Trials
Opportunities are available for individuals with multiple sclerosis (MS) to participate in several new clinical trials at the University of Maryland Center for Multiple Sclerosis Treatment and Research.
These studies are either currently enrolling or will be enrolling shortly.
The studies vary in design, duration, criteria for eligibility, number of MRI scans and other details. The following is a very brief summary of each study.
Clinical trial opportunities are constantly changing. Please keep in touch if you are interested in a trial.
Contact Information
For more information, please contact Kerry Naunton, RN, 410-328-5605 at the MS Center.
Current Clinical Trials
Early Aggressive Therapy for Multiple Sclerosis (Treat-MS) Trial Versus Traditional Treatment
The study, Treat-MS, aims to identify the most appropriate treatment strategy for people with MS, especially shortly after diagnosis, when it may be most possible to increase a patient's chances of preventing long-term disability.
Treat-MS will help inform patients and the broader healthcare community on whether MS patients would benefit from an earlier, aggressive therapy or from starting with traditional therapy, followed by a switch if relapses or new lesions occur, as the best way to prevent long-term disability.
Study assessments will include a detailed neurologic exam, MS Functional Composite, patient-completed questionnaires and standard clinical evaluations.
- Principal Investigator: Daniel Harrison, MD
- Eligibility: Participants must be 18 to 60 years old, have an MS diagnosis and meet requirements to start on the prescribed medications.
Adaptive Optics Retinal Imaging in Multiple Sclerosis
- Application No: HP-00087454
- Principal Investigator: Daniel Harrison, MD
- For more information, please contact Dr. Daniel Harrison at 410-328-4682 or dharrison@som.umaryland.edu.
This research is investigating the use of adaptive optics (AO) retinal imaging to assess how the eye is involved and affected by MS. We are searching for both people with multiple sclerosis and healthy volunteers without MS. Volunteers should be age 21 or older. The healthy volunteers should have no history of MS or eye disease.
Participants will undergo an initial eye exam and then a retinal imaging session. will be reimbursed for your time as well as any associated parking expenses.
Cielo Study
- Application No: HP-00100097
- Principal Investigator: David Benavides, MD, PhD
- For more information, please contact Dr. David Benavides at 410-328-1885 or dbenavides@som.umaryland.edu.
The purpose of this study is to see what the effect of satralizumab is on patients that have been diagnosed with autoimmune encephalitis. During this study, half of the participants will receive satralizumab and half will receive placebo. Your participation in this study would be completely voluntary.
Participants in this study will go through a screening phase, a double blind treatment phase (where neither you nor the doctor will know what you are receiving) and an extension phase. Participants will have a neurological and physical exam and have vital signs taken prior to beginning the study. Participants will have your blood sample collected at all visits for standard laboratory tests. Participants will also receive study medication given by injection.
